AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
We compare the 2024 outlook for index funds and target date funds to help you choose the right retirement path.
23,982 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Deregulation can tilt the odds for certain industries and investment themes. This guide explains how to spot opportun...
A bold government push is reshaping quantum tech and investing. Learn which three big stocks are positioned to win, a...
Tech leaders are shifting in 2026, prompting a clash between QQQ and VGT for access to Big Tech. This report breaks d...
If you’ve got $4,000, deciding between Dogecoin and Solana can feel overwhelming. This guide breaks down real-world u...
If you’re weighing Nvidia versus Alphabet for AI chip exposure, this guide breaks down the opportunity, the risks, an...
As the space economy matures, investors face a clear choice between Redwire and Rocket Lab. This guide breaks down bu...
Two consumer-facing stocks sit at a crossroads: GameStop is tightening its turnaround with a leaner footprint, while ...
Two cloud stock darlings sit at opposite ends of the growth vs profitability spectrum. This guide breaks down gitlab ...
As oil markets shift, offshore drilling and onshore completion services offer different paths to profits. This compar...
Two power players, two paths: Constellation Energy and Vistra offer differing mixes of stability and upside. This gui...
As 2026 unfolds, investors are weighing two distinct construction niche stocks. This guide breaks down how Concrete P...